**Mobile health technology-supported atrial fibrillation screening and integrated care: A report from the mAFA-II trial Long-term Extension Cohort**

Yutao Guo, MD, PhD1,2\*, Jun Guo, MD, PhD1, Xiangmin Shi, MD, PhD1, Yuan Yao MD3, Yihong Sun, MD, PhD4, Yunlong Xia, MD, PhD5, Bo Yu MD, PhD6, Tong Liu MD, PhD7, Yundai Chen, MD, PhD1, Gregory Y H Lip, MD1,2, On behalf of the mAF-App II Trial investigators\*

1Department of Cardiology, Chinese PLA General Hospital, Beijing, China; 2 Liverpool Centre for Cardiovascular Sciences, University of Liverpool, Liverpool, United Kingdom; and Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; 3Institute for Hospital Management Research, Chinese PLA General Hospital, Beijing, China; 4China-Japan Friendship Hospital, Beijing, China; 5Department of Cardiology, First Affiliated Hospital of Dalian Medical University, Dalian, China; 6Department of Cardiology, First Hospital of China Medical University, Shenyang, China; 7Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China

\* Drs Guo, Chen and Lip are joint senior authors.

**Corresponding Authors:**

* Associate Prof. Yutao Guo, Department of Cardiology, Chinese PLA General Hospital 28 Fuxing Road, Haidian Street, Beijing,100853 China Telephone: 86-10-55499311; E-mail: dor\_guoyt@hotmail.com
* Prof Gregory Y H Lip, University of Liverpool, Liverpool, UK. gregory.lip@liverpool.ac.uk

**Running head:** mAFA-II Long-term Extension Cohort.

**Abstract**

***Background*:** In the mobile Atrial Fibrillation App (mAFA)-II trial, the use of mobile health (mHealth) technology, incorporating AF screening and integrated management strategy, was associated with improved short-term clinical outcomes. The aim of this study was to report adherence/persistence and long term (≥1 year) clinical outcomes of the mAFA-II trial, with mHealth-supported optimised stroke prevention, symptom control and comorbidity management.

***Methods***: We studied an adult population screened for AF, where identified patients could enter a structured program of holistic and integrated care based on the ABC (Atrial fibrillation Better Care) pathway using mHealth with a mAFA intervention. In this cluster randomised trial, comparing mHeath intervention to usual care, the primary composite outcome was ‘stroke/thromboembolism, all-cause death and rehospitalization’.

***Results*:** The 1261 subjects (mean age 67.0 years, 38.0% female) who were followed up over one year (mean follow-up 687 (standard deviation, SD 191) days) in the intervention arm, had a lower risk of the composite outcome of ‘ischaemic stroke/systemic thromboembolism, death, and rehospitalization’ (hazard ratio, HR 0.18, 95% confidence interval, CI: 0.13-0.25, *P* < 0.001), compared to usual care (1212 subjects, mean age 70.1 years, 42.1% female). Of 842 patients using their smart devices for ‘Better symptom management’, 70.8% had good management adherence (monitoring time/follow-up since initial monitoring ≥ 70%), with the persistence of use of 91.7%.

***Conclusion***: Amongst AF patients with long term use (≥1 year) of mHealth technology for optimising stroke prevention, symptom control and comorbidity management, adherence/persistence was good and associated with a reduction in adverse clinical outcomes.

**Keywords** atrial fibrillation, screening, integrated care, smart technology

**1.Background**

The priorities of atrial fibrillation management include stroke prevention, decisions on rate or rhythm control and proactive management of comorbidities, as well as lifestyle changes. Given that atrial fibrillation patients can present to a diverse range of health care professionals, including general practitioners, non-cardiologists and cardiologists, there has been proposals to streamline the patient care pathway into a simple holistic and integrated approach that can be followed by all stakeholders and understood by patients.

One such approach to holistic atrial fibrillation care is the ABC (Atrial fibrillation Better Care) pathway, as follows: ‘A’ Avoid stroke. Anticoagulation; ‘B’ Better symptom management with patient-centred symptom directed rate or rhythm control; ‘C’ Cardiovascular risk and Comorbidity management, including lifestyle changes.1,2 The Atrial fibrillation Better Care pathway has been shown in post-hoc analyses of clinical trial cohorts and observational studies to be associated with improved clinical outcomes and reduces healthcare costs.3-5

Even before a patient enters the care pathway, we also need improvements in screening, and next, to show how detected atrial fibrillation patients can be entered into structured management programme. We previously reported that photoplethysmography based general-population atrial fibrillation screening approach was feasible, whereby 0.23% with “suspected” atrial fibrillation from a screened population of 246,541 received a notification of suspected atrial fibrillation, of which 87% were confirmed as atrial fibrillation, and 80% of high-risk patients were subsequently anticoagulated.6 Short term outcomes (mean followup 262 days) of such identified atrial fibrillation patients randomized into the mAFA-II (mobile Atrial Fibrillation App) cluster randomized trial using mobile health (mHealth) based integrated care management found a significant reduction in the composite outcome of ‘ischaemic stroke/systemic thromboembolism, death, and rehospitalization’, compared to usual care7. However, the long-term adherence/persistence of mobile health technology use and the impact on clinical outcomes, remains uncertain although the approach has been increasingly proposed for chronic disease management. The mAFA programme is still ongoing (patients can still download and start using the mAF App), but we need to answer the question on ‘long term users’ (ie. using mHealth for >1 year) which is the current specific focus of the present paper.

In the present report from the mAFA-II trial, the objective was to report adherence/ persistence and long term (≥1 year) clinical outcomes of the mAFA-II trial, with optimised stroke prevention, symptom control and comorbidity management. Hence, the subgroup of atrial fibrillation patients with mobile health technology use and follow up of over one year were included into this ancillary analysis.

**2.Methods**

The mobile **A**trial **F**ibrillation **A**pplication (mAFA) programme, which investigated mobile health (mHealth) technology for improved screening and optimised integrated care in atrial fibrillation, has been described previously8. In brief, the programme included the pre-mAFA phase of screening for atrial fibrillation in the general population.**6** Then those with identified atrial fibrillation were considered for entry into the mAFA II cluster randomized trial9, to validate an integrated care approach based on the Atrial fibrillation Better Care pathway.

The study was approved by the Central Medical Ethics Committee of Chinese PLA General Hospital (Approval number: S2017-105-02) and registered on the WHO International Clinical Trials Registry Platform (ICTRP) [chictr.org.cn; registration number ChiCTR-OOC-17014138 (http://www.chictr.org.cn/showprojen.aspx?proj=24191)]. The study was compliant with the Declaration of Helsinki.

*2.1. Study population*

Subjects aged over 18 years old across China, with compatible smart phone and devices were freely available for continuous photoplethysmography-based pulse monitoring after providing electronically signed study informed consent, between October 26, 2018 and June 16, 2020. The subjects who received the notification of ‘suspected’ atrial fibrillation were further confirmed with the diagnosis of atrial fibrillation (or not) upon the clinical evaluation, electrocardiography (ECG), or 24 hour Holter monitoring by mAFA programme health providers8. At least 14-days monitoring was proposed for the subjects; but they could freely monitor their pulse rhythm beyond 14 days8. All ‘identified atrial fibrillation’ in atrial fibrillation screening phase were followed up by mAFA programme telecare team, but in this long-term cohort, we focused on the subgroup of subjects with ‘identified’ atrial fibrillation followed up for over one year.

*2.2. mAFA II Long-term Cohort*

Following a pilot feasibility study (mAFA-I)10, we updated the mobile Atrial Fibrillation App with the Atrial fibrillation Better Care pathway on February 22, 2018 for conducting the mAFA-II clinical trial. The mAFA II trial participants were consecutively recruited from those referred from the initial atrial fibrillation screening programme (‘pre-mAFA’)6, or from the out-patient and in-patient departments from 40 participating centres in China, between June 1, 2018 and December 1, 2019. This trial was designed as a cluster randomised trial which compared mobile health technology intervention with the mobile Atrial Fibrillation App, against ‘usual care’ at a cluster level.9 The centre selection, cluster randomization, patient's enrolment, and hospital type have been reported previously.8 To report adherence/persistence and long term (≥1 year) clinical outcomes, the subgroup of atrial fibrillation patients using mobile health technology intervention with follow up over one year were included, as the mAFA II Long-term cohort (Figure 1).

Atrial fibrillation patients allocated to the mobile health technology intervention could download the mobile Atrial Fibrillation App, to follow an integrated care management approach using the Atrial fibrillation Better Care pathway, as follows:8

* **‘A’ Anticoagulation to Avoid stroke** – Anticoagulation with non-vitamin K antagonist oral anticoagulant or well-managed warfarin;
* **‘B’ Better symptom management** with patient-centred symptom-directed shared decisions for rate or rhythm control;
* **‘C’ Cardiovascular risk and comorbidity management** (blood pressure, sleep apnoea, diabetes etc.) plus lifestyle changes (weight reduction, regular exercise, reducing alcohol/stimulants, psychological morbidity, smoking cessation, etc.).

For **‘A’ Anticoagulation to Avoid stroke,** the laboratory parameters (international normalized ratio, renal/hepatic function, etc.) could be tested in local hospitals, with data uploaded by the mobile Atrial Fibrillation App. Anticoagulant quality monitoring, dynamic risk bleeding assessment11, and guideline-adherent dosage adjustment based on age, renal/liver function changes, etc., were provided by the mobile Atrial Fibrillation App, and management further confirmed/modified by doctors in the mAFA programme network.8,9

For **‘B’ Better symptom management**, patients could report atrial fibrillation symptoms, compliant with European Heart Rhythm Association classification12, but also could monitor their pulse rhythm for ‘suspected’ atrial fibrillation, together with the ‘atrial fibrillation burden’ during their monitoring time if they had photoplethysmography-based smart devices. Patient advice (drugs, lifestyle, or behavioral changes, etc.) of rate or rhythm control would be given to the patients by in-built communication function with doctors using mAFA. For

For **‘C’ Cardiovascular risk and comorbidity management**, optimized management targets for risk factors and lifestyle recommendations were based on guidelines, as previously described.9

Patients allocated to **usual care** received their ‘usual care’ treatments by local health providers according to their local clinical practice.9 Power calculations for the main mAFA-II trial have been previously published8 9, and the current ancillary analysis only focuses on the subgroup with long term usage.

*2.3. Outcomes*

In this mAFA II trial long-term cohort, the subgroup with mobile health technology use and follow up of over one year were enrolled into this ancillary analysis. Of note, all patients within this subgroup were included, and those with clinical outcomes occurring at <1 year, were included into the intention to treat analysis, to report outcomes of mobile health technology intervention vs. usual care.

The *primary endpoint* was the composite of stroke/thromboembolism, all-cause death, and rehospitalization, which reported previously.8,9. Reasons for rehospitalization included any cause for atrial fibrillation, heart failure, thromboembolism, major bleeding, coronary artery disease, and other cardiovascular disease. The *secondary outcomes* included event rates for the components of the primary endpoint. We also focused on outcomes related to the components of the Atrial fibrillation Better Care pathway as follows:

* **‘A’ Anticoagulation to Avoid stroke** outcomeswere assessed with thromboembolism and bleeding events.
* **‘B’ Better symptom management** outcomes were evaluated with regard to recurrent atrial fibrillation or related symptoms.
* **‘C’ Cardiovascular risk and comorbidity management** outcomes for this ancillary analysis were assessed with regard to atrial fibrillation patients with heart failure, and blood pressure management over the follow-up period.

*2.4. Adherence and persistence*

The adherence and persistence with mobile health technology use was evaluated, as follows: i) the rate of subjects with suspected atrial fibrillation from photoplethysmography-based screening transferred into the mAFA trial programme over one year; and ii) the adherence/persistence of patients using atrial fibrillation on their smart devices.

*2.5. Statistical Analysis*

Data with a normal distribution were presented as a mean (standard deviation, SD). Data with a non-normal distribution were presented as median (interquartile range, IQR). The proportions of 'suspected' and 'confirmed' atrial fibrillation from the general population screening phase was calculated, stratified by gender and age. Subject-reported comorbidities among general population, 'suspected' atrial fibrillation, and 'confirmed' atrial fibrillation were investigated for the underlying risk factors in general population, given this was a large cohort involving more than one million. For these identified atrial fibrillation from screening approach transferred into mAFA trial programme over one year, the utilization of the mobile Atrial Fibrillation App was evaluated.

The rates of thromboembolism, bleeding events, recurrent atrial fibrillation, heart failure, rehospitalization, and all-cause death for patients using mobile Atrial Fibrillation App were compared with usual care. Rates are expressed as 'events/per 1000 patient-years, but while some patients suffered more than one event, the follow-up survival analysis was only calculated for the time to first event.

Given that atrial fibrillation patients with ‘usual care’ did not routinely monitor their blood pressure in a systematic manner, blood pressure changes could not be compared between patients allocated to mAFA trial intervention and usual care clusters. Hence, the changes on blood pressure levels were only described for patients with mAFA trial intervention.

 Cox proportional hazards models adjusted for cluster effect, and baseline risk factors, were used to analyse the primary composite outcome of stroke/thromboembolism, all-cause death, and rehospitalization over one year. Adjusted baseline risk factors included age, gender, hypertension, coronary artery disease, diabetes mellitus, heart failure, peripheral artery disease, pulmonary disease (chronic obstructive pulmonary disease, obstructive sleep apnea syndrome, pulmonary hypertension), dilated cardiomyopathy, prior ischaemic stroke, prior other thromboembolism, prior intracranial bleeding, prior other bleeding, liver/ renal dysfunction.

The adherence of using mobile health technology was calculated, defined as the rate of the monitoring time using smart devices divided by the follow-up period since initial monitoring. The persistence of mobile health technology use for patients was defined as any of uploading medical materials, consulting with mAFA trial programme health providers, participation/involvement in educational programs, etc. during the follow up period. We also report the rate of subjects with suspected atrial fibrillation from the screening phase, transferred into the mAFA trial over one year, and the adherence/persistence of patients. Finally, the utilisation of the mobile Atrial Fibrillation App over time was observed, to describe use the mobile health technology application during coronavirus disease 2019 outbreak in China, since January 20, 2020.

A two-sided P-value < 0.05 was considered as statistically significant. The 95% confidence intervals (CIs) were calculated with Wilson score method without continuity correction. All statistical analyses were conducted using IBM SPSS Statistics, version 22.0 (SPSS Inc), and MedCalc version 19. 0.4 (MedCalc Software).

**3. Results**

*3.1. General Population-Based atrial fibrillation Screening*

Between October 26, 2018 and June 16, 2020, there were 1,463,383 subjects who downloaded the mobile Atrial Fibrillation App for screening, and of these 1,187,381 subjects (mean age 35.4, SD 11.5, 17.3% female) had compatible smart devices. Of the latter, 3471 subjects received a notification of 'suspected' atrial fibrillation, and 2088 'suspected' cases (60.1%, 2088/3471; mean age 56.2 (SD 13.8), 16.3% female) were effectively followed up by the mAFA programme health providers (**Figure 1**). Those with confirmation of ‘suspected’ atrial fibrillation are shown in Supplemental Figure 1.

Sleep apnea (40.9%) and hypertension (39.8%) were most common self-reported comorbidities in this screening population (**Table 1**). There were 449 with confirmed atrial fibrillation (23.0%, mean age 55.7, SD 13.6 years; 15.4% female) with follow-up of over one year and >99% (n=445) used the mobile Atrial Fibrillation App for their self-management with the Atrial fibrillation Better Care pathway**(Figure 1**).

The proportion of suspected atrial fibrillation among general population increased with age, with the highest prevalence of 5.84% (321/5492, 95% CI, 5.25-6.50) in subjects aged over 75 years old. The proportions of 'suspected' and 'confirmed' atrial fibrillation are shown in Supplemental Figure 2. The prevalence of 'suspected' atrial fibrillation stratified by age strata, ranged from 0.04%-5.38% in females, and 0.06%-6.28% in males (Supplemental Figure 3).

*3.2. Atrial fibrillation Better Care pathway*

Baseline characteristics of the intervention and usual care arms from a total of 40 centres participating in this cluster randomised trial are shown in Supplementary Table 2.

The ‘intervention group’ consisted of 1261 subjects (mean age 67.0 years, 38.0% female) from 20 clusters who were followed up for over one year (mean follow-up 687 (SD 191) days; median 701 days (IQR 489-841). These were compared to 1212 subjects (mean age 70.1 years, 42.1% female) managed with ‘usual care’ with a mean follow-up of 514 (SD 167) days (median 546 (IQR 394-632) from another 20 research centers.

Rates of clinical outcomes (thromboembolism, bleeding events, recurrent atrial fibrillation and its symptoms, heart failure, and rehospitalization) were lower in patients allocated to intervention, compared with usual care (all p < 0.05) (**Table 2,** Supplementary Table 3**).**

Compared to usual care, patients allocated to intervention had a lower risk of the composite outcome of ‘ischaemic stroke/systemic thromboembolism, death, and rehospitalization’, adjusted for baseline risk factors (hazard ratio, HR 0.18, 95% CI: 0.13-0.25, *P* < 0.001) (**Figure 2**, Supplemental Figure 4, Supplementary Table 4).  Cumulative incidences of all-cause death and rehospitalization are shown in Supplemental Figure 5. Atrial fibrillation patients allocated to intervention also showed improved blood pressure control over time (Supplemental Figure 6).

*3.3. Adherence and Persistence*

There were 842 atrial fibrillation patients (mean age ± SD, 51.8±14.2; 15.0% female) using mAFA intervention, particularly for the ‘B’ criterion, ie. Better symptom management. Of these, 70.8% of patients had good management adherence (monitoring time/follow-up since initial monitoring ≥ 70%), with the persistence of use of 91.7% (**Figure 3**). The ‘young’ patients, or with paroxysmal AF seemly appeared the much better trend of adherence of mobile health supported pathway B Better Symptom management with smart device over 70% (Supplemental Figure 7, 8.). After coronavirus disease 2019 outbreak on January 20, 2020 in China, the monthly active users of the mobile Atrial Fibrillation App increased over time (Supplemental Figure 9).

**Discussion**

Amongst atrial fibrillation patients with long term use (≥1 year) of mobile health technology for optimising stroke prevention, symptom control and comorbidity management, their adherence/persistence was good and associated with a reduction in adverse clinical outcomes, when compared to those managed with usual care. Second, patients using the mobile Atrial Fibrillation App had a reduced risk for the primary composite outcome of ‘ischaemic stroke/systemic thromboembolism, death, and rehospitalization’, compared to usual care. Third, >70% of subjects using mobile health technology had good management adherence, with the persistence of use of 91.7%.

As far as we are aware, the mAFA programme is the first mobile health technology based programme for atrial fibrillation screening, followed by a structured patient care pathway based on the principal components of atrial fibrillation management. The present analysis focused on the subgroup of participants enrolled for ≥1 year was pre-planned to assess adherence/persistence and long-term outcomes, given that the overall mAFA programme is continually enrolling subjects, using the mobile Atrial Fibrillation App.

Atrial fibrillation confers a significant health, economic, and social burden, with the increased risk of stroke, death, dementia, heart failure and hospitalization.13 Hence, its early diagnosis with appropriate management would help prevent the main atrial fibrillation-related complications. However, even before the patient with atrial fibrillation enters any management pathway, there is the need to improve the detection of this arrhythmia.

Smart technology is increasingly deployed to help with screening for atrial fibrillation. Indeed, the continuous monitoring of pulse rhythm on home with wearable devices is practical, which has been proven to improve the early identification of atrial fibrillation.6,14 Following its detection, the next important step is to manage these identified atrial fibrillation patients with a holistic integrated approach, to achieve the main goals of atrial fibrillation management. While much attention has focused on stroke risks of atrial fibrillation, we recognize the high mortality and other adverse outcomes associated with this common arrhythmia. Indeed, of the mortality outcomes associated with atrial fibrillation, only one in 10 is stroke related and > 7 in 10 are cardiovascular.15,16

Efforts are therefore being directed to streamline the management of atrial fibrillation in an integrated manner, which needs a simple approach that can be followed by all healthcare practitioners (general practioners, non-cardiologists, cardiologists), the patient, and their carers. This has led to the proposal of the ABC (Atrial fibrillation Better Care) pathway, whereby ABC pathway compliance has been associated with improved clinical outcomes and lower healthcare costs.3-5 Such a uniform message (‘Simple as ABC….’) applicable to all stakeholders is important given that conflicting information received from different healthcare providers can negatively affect adherence with management.17

The benefits of integrated care on atrial fibrillation outcomes are increasingly evident. In the meta analysis by Gallagher et al. demosntated that the use of an integrated care approach in atrial fibrillation reduced the risk for cardiovasular hospitalisations by 42%.18 Indeed, an integrated care apporach in the present mAFA II trial long term extension cohort reduced the risk for rehospitalisation by 31%. Other nurse-driven (or nurse-led) integrated care approachs have also been demonstrated to be clinically beneficial for atrial fibrillation patients.19-21

However, there are growing challenges on how best to apply mobile health technology into atrial fibrillation management, with marked heterogeneity of published findings. In the SUPPORT-AF study, the supportive tools based on electronic medical records, supplemented by email notifications, related to anticoagulant prescribing was feasible, but did not increase anticoagulant use in patients with atrial fibrillation. 22 Patient refusal or non-adherence was suggested as the main reason for a patient being non-anticoagulated. Also, it may be inadequate to simply inform physicians with the rate of anticoagulant use by patients under their care, but there is the need to support the physicians to ascertain the underlying barriers to anticoagulant use and assess stroke (and bleeding) risks, while improving patient’s knowledge as part of a streamlined integrated care management pathway approach.

In the mAFA-II trial, we previously reported the short term outcomes (mean follow-up of 262 days) associated with mobile health management based on the Atrial fibrillation Better Care pathway, with a significant reduction in the composite outcomes, that was largely driven by hospitalisations7. In the present analysis of those (long term) mAFA participants with ≥ 1 year use/followup, there were maintained reductions in the composite outcome and hospitalization using mAFA trial intervention. Importantly, for the individual components of the ABC pathway, there were significant reductions in ischaemic stroke, extracranial bleeding, recurrent atrial fibrillation and atrial fibrillation-related symptoms, as well as heart failure during long term followup. This was associated with good adherence and persistence with the mobile Atrial Fibrillation App and the overall mAFA programme.

We did not observe a significant difference in all-cause death alone, perhaps associated with significant reduction in ischaemic stroke over one year in patients on mAFA intervention compared to usual care (Supplementary Figure 5). Another possibility is that the coronavirus disease 2019 outbreak might have led to suboptimal atrial fibrillation ‘usual-care’ management (e.g. less anticoagulant monitoring) leading with additional cardiovascular events.23 Suboptimal ‘usual-care’ management includes a decline in oral anticoagulant use without mobile Atrial Fibrillation App intervention, as previously reported11, which could contribute to worse outcomes (including more ischaemic strokes) in those allocated to the ‘usual care’ arm of the trial.

Uptake and use of the mobile Atrial Fibrillation App increased even more during the recent coronavirus disease 2019 pandemic period in China. Indeed, digital wearables, telehealth/E-visit, remote management, etc. have been proposed for disease management by academic societies since the coronavirus disease 2019 outbreak.24 A similar program, e.g. TeleCheck-AF programme, is carrying out atrial fibrillation management through teleconsultations, but without any outcome data.25 The present study provides some descriptive evidence for mobile health technology for atrial fibrillation management during the current challenging coronavirus disease 2019 pandemic.

*Limitations*

Important limitations should be recognized. This study was performed in a healthcare system with widespread smartphone use, and the results may not be generalizable to other healthcare settings. While we conducted a cluster randomized trial and have adjusted for cluster effect and baseline risk factors, residual confounding may still be present. Moreover, there was possibly selection bias with more male, younger subjects during atrial fibrillation screening phase, although the baseline characteristics were balanced in mAFA-II trial phase of the programme.

The present report which focuses on the subgroup of patients using the mobile Atrial Fibrillation App for over one year, so the patients with less than a year of follow-up were excluded from this analysis. Nonetheless, any ‘hard’ clinical outcomes in all patients from this subgroup (ie. with >1 year use), even those occurring at < 1 year were also recorded, but less censored data could bias the outcome analysis. Of note, we have also compared the baseline characteristics of patients with mobile Atrial Fibrillation App use < 1 year and ≥1 year (Supplementary Table 5). The patients enrolled into mAFA programme for over one year were more likely to have more comorbidities, compared with patients using the mobile Atrial Fibrillation App for < 1 year. Finally, we found generally good adherence and persistence with the mAFA programme, but this may reflect our relatively young mean age of the study cohort. Further analyses from the mAFA II trial would focus on the elderly and those with clinical complexity, such as multimorbidity.

**Conclusion**

Amongst atrial fibrillation patients with long term use (≥1 year) of mobile health technology for optimising stroke prevention, symptom control and comorbidity management, adherence/persistence was good and associated with a reduction in adverse clinical outcomes**.**

**Acknowledgements**

The Authors would like to thank to Weixin Li, who worked in the Mobile Atrial Fibrillation Application Telecare team, Atrial fibrillation Center, Chinese PLA General Hospital, for help with data extraction and follow-up of the patients. We would also like to thank to Xiaoxian Wang for the kind support for data analysis.

**Funding**

This academic-led research project was funded by the National Natural Science Foundation of China (No. 8147413), National Key Research and Development Project of China (2018YFC2001200), and was funded by the Health and Family Planning Commission of Heilongjiang Province, China (2017-036), and partly supported by the NIHR Global Health Research Group on Atrial Fibrillation management at the University of Birmingham, UK. This study was an investigator-initiated project, with limited funding by independent research and educational grants. Funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report. There was no funding from commercial companies.

**Declaration of Competing Interest**

GYHL: Consultant for Bayer/Janssen, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseon and Daiichi-Sankyo. Speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. No fees are directly received personally. Other authors: None declared.

All authors had access to the data. All authors contributed to the data interpretation and critical review of the work, have approved the final manuscript and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriate.

**Appendix A. Supplementary data**

Supplementary data to this article can be found online.

**References**

1. Lip GYH. The ABC pathway: an integrated approach to improve AF management. *Nat Rev Cardiol* 2017;14:627-628.

2. Lip GYH, Banerjee A, Boriani G, Chiang CE, Fargo R, Freedman B, et al. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. *Chest* 2018;154:1121-1201.

3. Proietti M, Romiti GF, Olshansky B, Lane DA, Lip GYH. Improved Outcomes by Integrated Care of Anticoagulated Patients with Atrial Fibrillation Using the Simple ABC (Atrial Fibrillation Better Care) Pathway. *Am J Med* 2018;131:1359-1366.e1356.

4. Pastori D, Pignatelli P, Menichelli D, Violi F, Lip GYH. Integrated Care Management of Patients With Atrial Fibrillation and Risk of Cardiovascular Events: The ABC (Atrial fibrillation Better Care) Pathway in the ATHERO-AF Study Cohort. *Mayo Clin Proc* 2019;94:1261-1267.

5. Yoon M, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS, et al. Improved Population-Based Clinical Outcomes of Patients with Atrial Fibrillation by Compliance with the Simple ABC (Atrial Fibrillation Better Care) Pathway for Integrated Care Management: A Nationwide Cohort Study. *Thromb Haemost* 2019;19:1695-1703.

6. Guo Y, Wang H, Zhang H, Liu T, Liang Z, Xia Y, et al. Mobile Photoplethysmographic Technology to Detect Atrial Fibrillation. *J Am Coll Cardiol* 2019;74:2365-2375.

7. Guo Y, Lane DA, Wang L, Zhang H, Wang H, Zhang W, et al. Mobile Health Technology to Improve Care for Patients With Atrial Fibrillation. *J Am Coll Cardiol* 2020;75:1523-1534.

8. Guo Y, Lane DA, Wang L, Chen Y, Lip GYH. Mobile Health (mHealth) technology for improved screening, patient involvement and optimising integrated care in atrial fibrillation: The mAFA (mAF-App) II randomised trial. *Int J Clin Pract* 2019;73:e13352.

9. Guo Y LD, Wang L, Zhang H, Wang H, Zhang W, Wen J, Xing Y, Wu F, Xia Y, Liu T, Wu F, Liang Z, Liu F, Zhao Y, Li R, Li X, Zhang L, Guo J, Burnside G, Chen Y, Lip GYH and on behalf of the mAF-App II Trial Investigators. . Mobile health to improve optimization of integrated care in patients with atrial fibrillation: mAFA-II trial. *J Am Coll Cardiol* 2020;75:1523-1534.

10. Guo Y, Chen Y, Lane DA, Liu L, Wang Y, Lip GYH. Mobile Health Technology for Atrial Fibrillation Management Integrating Decision Support, Education, and Patient Involvement: mAF App Trial. *Am J Med* 2017;130:1388-1396 e1386.

11. Guo Y LD, Chen Y, Lip GYH; mAF-App II Trial investigators. Regular Bleeding Risk Assessment Associated with Reduction in Bleeding Outcomes: The mAFA-II Randomized Trial. *Am J Med* 2020 Apr 12.

12. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J* 2016;37:2893-2962.

13. Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. *Int J Stroke* 2020:1747493019897870.

14. Perez MV, Mahaffey KW, Hedlin H, Rumsfeld JS, Garcia A, Ferris T, et al. Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation. *N Engl J Med* 2019;381:1909-1917.

15. Fauchier L, Villejoubert O, Clementy N, Bernard A, Pierre B, Angoulvant D, et al. Causes of Death and Influencing Factors in Patients with Atrial Fibrillation. *Am J Med* 2016;129:1278-1287.

16. Pokorney SD, Piccini JP, Stevens SR, Patel MR, Pieper KS, Halperin JL, et al. Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. *J Am Heart Assoc* 2016;5:e002197.

17. Moudallel S, van den Bemt BJF, Zwikker H, de Veer A, Rydant S, Dijk LV, et al. Association of conflicting information from healthcare providers and poor shared decision making with suboptimal adherence in direct oral anticoagulant treatment: A cross-sectional study in patients with atrial fibrillation. *Patient Educ Couns* 2020.

18. Gallagher C, Elliott AD, Wong CX, Rangnekar G, Middeldorp ME, Mahajan R, et al. Integrated care in atrial fibrillation: a systematic review and meta-analysis. *Heart* 2017;103:1947-1953.

19. van den Dries CJ, van Doorn S, Rutten FH, Oudega R, van de Leur S, Elvan A, et al. Integrated management of atrial fibrillation in primary care: results of the ALL-IN cluster randomized trial. *Eur Heart J* 2020.

20. Wijtvliet E, Tieleman RG, van Gelder IC, Pluymaekers N, Rienstra M, Folkeringa RJ, et al. Nurse-led vs. usual-care for atrial fibrillation. *Eur Heart J* 2020;41:634-641.

21. Hendriks JML, Tieleman RG, Vrijhoef HJM, Wijtvliet P, Gallagher C, Prins MH, et al. Integrated specialized atrial fibrillation clinics reduce all-cause mortality: post hoc analysis of a randomized clinical trial. *Europace* 2019.

22. Kapoor A, Amroze A, Vakil F, Crawford S, Der J, Mathew J, et al. SUPPORT-AF II: Supporting Use of Anticoagulants Through Provider Profiling of Oral Anticoagulant Therapy for Atrial Fibrillation: A Cluster-Randomized Study of Electronic Profiling and Messaging Combined With Academic Detailing for Providers Making Decisions About Anticoagulation in Patients With Atrial Fibrillation. *Circ Cardiovasc Qual Outcomes* 2020;13:e005871.

23. Holt A, Gislason GH, Schou M, Zareini B, Biering-Sørensen T, Phelps M, et al. New-onset atrial fibrillation: incidence, characteristics, and related events following a national COVID-19 lockdown of 5.6 million people. *Eur Heart J* 2020.

24. Lakkireddy DR, Chung MK, Gopinathannair R, Patton KK, Gluckman TJ, Turagam M, et al. Guidance for Cardiac Electrophysiology During the Coronavirus (COVID-19) Pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology, American Heart Association. *Heart Rhythm* 2020.

25. Linz D, Pluymaekers N, Hendriks JM. TeleCheck-AF for COVID-19. *Eur Heart J* 2020;41:1954-1955.

**FIGURE LEGENDS**

**Figure 1 Flow chart of AF screening and mAFA Long-term Extension Cohort with over one-year follow-up.** \*mAFA: mobile Atrial Fibrillation Application. App: application. AF: atrial fibrillation. SD: standard deviation.

**Figure 2 Cumulative incidence of the composite outcome of ischaemic stroke/TE, death, and rehospitalization.** \*mAFA: mobile Atrial Fibrillation Application. TE: other systemic thromboembolism. HR: hazard ratio. CI: confidence interval.

**Figure 3 Adherence of patient-centred symptom-directed rate or rhythm control with smart devices using mAFA (B criterion of ABC pathway).**

\* *P* < 0.001, compared among the adherence strata. There were 842 atrial fibrillation patients using photoplethysmography-based smart devices focused on ‘B’ criterion (Better symptom management): 70.8% had management adherence (monitoring time/follow-up since initial monitoring) of ≥ 70%, with the persistence of use of 91.7%.

mAFA: mobile atrial fibrillation Application.